We are live on
!
Find out more
AbCellera Biologics
ABCL
ABCL
138 hedge funds and large institutions have $434M invested in AbCellera Biologics in 2026 Q1 according to their latest regulatory filings, with 20 funds opening new positions, 54 increasing their positions, 34 reducing their positions, and 26 closing their positions.
New
Increased
Maintained
Reduced
Closed
59% more repeat investments, than reductions
Existing positions increased: 54 | Existing positions reduced: 34
17% more capital invested
Capital invested by funds: $371M → $434M (+$63.4M)
4.78% more ownership
Funds ownership: 36.22% → 40.99% (+4.8%)
4% less funds holding
Funds holding: 144 → 138 (-6)
23% less first-time investments, than exits
New positions opened: 20 | Existing positions closed: 26
33% less call options, than puts
Call options by funds: $9.08M | Put options by funds: $13.6M
Holders
138
Holders Change
-6
Holders Change %
-4.17%
% of All Funds
1.7%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
20
Increased
54
Reduced
34
Closed
26
Calls
$9.08M
Puts
$13.6M
Net Calls
-$4.52M
Net Calls Change
-$8.45M
Top Buyers
| 1 |
TWC
TD Waterhouse Canada
Toronto,
Ontario, Canada
|
+$34.3M |
| 2 |
Two Sigma Investments
New York
|
+$17.1M |
| 3 |
BBA
Baker Bros. Advisors
New York
|
+$9.9M |
| 4 |
JFG
Jefferies Financial Group
New York
|
+$9.88M |
| 5 |
Alyeska Investment Group
Chicago,
Illinois
|
+$9.33M |
Top Sellers
| 1 |
Renaissance Technologies
New York
|
-$3.16M |
| 2 |
Morgan Stanley
New York
|
-$2.8M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$2.79M |
| 4 |
Goldman Sachs
New York
|
-$2.13M |
| 5 |
Jane Street
New York
|
-$1.98M |
